cyrilzakka/clinical-trials huggingface dataset:
Postoperative Prognosis Management Service Based mHealth for Gastric Cancer Patients

Recently, the use of mobile health is increasing for the purpose of managing prognosis such as recurrence, survival and quality of life by using a wearable smart band together with a smartphone application. In the era of the 4th revolution, mobile health for the purpose of comprehensive prognosis for cancer patients is becoming a very good tool. As a result of applying a mobile application for health management (nutrition, health education, exercise, etc.) to 203 gastric cancer or colon cancer patients undergoing chemotherapy in the previous study, gastric cancer patients are most interested in health-related education and information.

As such, it was possible to confirm the clinical significance of short-term and temporary health care through mobile applications and smart bands during the treatment process for gastric cancer patients, but the study was insufficient to generalize the number of subjects. Therefore, until now, the results of a multicenter randomized-control study have not been found after long-term application as a supportive tool from immediately after surgery (before treatment) to during the treatment process.

Therefore, in gastric cancer patients who need prognosis management after surgery, we will investigate the effect of mobile application with smart band which has a modular structure reflecting the treatment method and treatment process after surgery.

This study targets patients who underwent gastric cancer surgery, an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months. Control group was provided general education through the hospital brochure. Evaluation will be conducted 2-3days after surgery (before discharge), and at 1, 3, 6, and 12 months after surgery.


Eligibility Criteria:
Inclusion Criteria:

* AJCC stage I-III who has undergone radical gastric cancer surgery (chemotherapy, radiation therapy is irrelevant)
* Patients aged 19 to 75 years old
* Those who can use prognosis management applications and can perform regular follow-up inspections outpatients
* Patients carrying Android or iOS smartphones
* Patients who voluntarily decide to participate and give written consent after hearing detailed explanations about this study

Exclusion Criteria:

* Those who have difficulty using gastric cancer applications (exercise performance, diet management, etc.) due to severe underlying diseases, neuromusculoskeletal diseases, cognitive, and visual impairments
Burn Coverage of Burn by Tilapia Fish Skin

The goal of this experimental study is to compare TFS and regular dressings as coverage for acute thermal burns. The main question it aims to answer is:

Is TFS effective in treating thermal burns? burn induction was done on rabbits to obtain second-degree thermal burn, followed by coverage with TFS

Nile Tilapia Fish Skin (NTFS) has been suggested as an option for biological material for the management of burns. Nile Tilapia Fish Skin also presented a large composition of type I collagen, morphology similar to human skin and high resistance and tensile extension at the break. We chose Baladi rabbits for their relatively ease of handling, accommodation and resistance to surgical aggressions and infectious processes, with low mortality. However, the choice of male rabbits is due to variations in hormonal cycles in females that could intervene in the process of tissue repair.

This experimental model was established to evaluate healing process and outcome results after application of Tilapia Fish Skin on acute contact thermal that was done in order to obtain injuries with the same size and depth.

Eligibility Criteria:
Inclusion Criteria:

- healthy male one year old rabbit

Exclusion Criteria:

* female unhealthy rabbits
Impact of Smoking, Benzodiazepine (BZD) Use and Obesity on Severe Obstructive Sleep Apnea (sOSA)

In this study the investigators will analyze the influence of smoking, benzodizepine use, and obesity among patients with severe Obstructive Sleep Apnea (sOSA).

This study is a retrospective study. Patients enrolled: all patients with a PSG (polysomnography) between 1st January 2014 and 30th June 2015.

First analysis: influence of smoking, benzodiazepine use, and obesity on the AHI (Apnea Hypopnea Index: the number of apnea and hypopnea per hour of sleep).

Second analysis: only among patients with sOSA: influence of smoking, benzodiazepine use, and obesity on sleep fragmentation and night oximetry.

Eligibility Criteria:
Inclusion Criteria:

* All patients registered for an overnight PSG at Clinique Saint-Luc of Bouge

Exclusion Criteria:

* None
Evaluation of a Novel Medical Device to Facilitate Gel Instillation During Change of Long-term Urinary Catheters

A randomized, open label, controlled, parallel group study to investigate difference between regional standard procedure and a novel modified procedure (using an additional novel device to facilitate gel installation) for changing long-term indwelling urinary catheters.

This is a randomized, open label, controlled, parallel group study, which comprises one visit that includes: assessment for eligibility, randomization to one of two treatment alternatives, followed by the actual intervention and evaluation of outcomes.

The interventions are either change of catheter according to the regional standard procedure (the comparator group) or change of catheter with the additional use of the novel device to facilitate gel instillation and a slightly modified procedure (the experimental group).

Eligibility Criteria:
Inclusion Criteria:

* The patient has an indwelling catheter and a primary diagnosis that justify continued catheter use
* The patient provides informed consent prior to any study specific procedures
* The patient is considered to benefit from participation in the clinical study

Exclusion Criteria:

* The patient do not consent to participate in the study
* Trauma to urethra or bladder
* Infection to urethra or bladder
* Other diagnosis that contraindicates participation in the clinical study as judged by the responsible physician
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.

The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone before autotransplant, and in elderly patients in combination with conventional chemotherapy and as consolidation/maintenance therapy in young and elderly patients at plateau-phase.

MY-TAG : Thalidomide as induction treatment before high dose therapy, in young patients MY-DECT : Thalidomide as induction treatment with conventional chemotherapy, in elderly patients MY-PLAT : Thalidomide and Dexamethasone at plateau-phase, after high dose therapy or conventional chemotherapy

Eligibility Criteria:
Inclusion Criteria:

* for MY-TAG(auto-transplant): age 18-65, multiple myeloma Salmon-Durie stage II, stage III and symptomatic stage I (lytic bone lesion or a 25 % increase of monoclonal protein)
* for MY-DECT (conventional chemotherapy) : qge 66-80, multiple myeloma Salmon-Durie stage II, stage III and symptomatic stage I (lytic bone lesion or a 25 % increase of monoclonal protein)
* for MY-PLAT (maintenance at plateau-phase): patients treated in MY-TAG or MY-DECt with at least a minimal response (25 % decrease of M protein)3-6 months after autotransplant or last chemotherapy

Exclusion Criteria:

* for MY-TAG : age 66 or more, smoldering stage I multiple myeloma, previous therapy, plasma cell leukemia,creatinine \> 300 micromol/L, liver failure, anthracycline contra-indicated, thalidomide contra-indicated, corticosteroid contra-indicated
* for MY-DECT : age \< 66 or \> 80, smoldering stage I multiple myeloma, previous therapy, plasma cell leukemia,creatinine \> 300 micromol/L, liver failure, thalidomide contra-indicated, corticosteroid contra-indicated
* for MY-PLAT : no response or progressive disease, randomization \> 6 m since autotransplant or last chemotherapy, creatinine \> 300 micromol/L, liver failure, thalidomide contra-indicated, corticosteroid contra-indicated
Clinical Characteristics and Prognosis of Aortic Dissection in China (CLASSIC)

This study will construct a retrospective-prospective long-term follow-up cohort and management system for aortic dissection through a multicentre collaborative network. This study aims to investigate the disease characteristics, progression patterns, clinical features, natural course and factors affecting the disease course and prognosis of patients with aortic dissection by retrospectively collecting data and prospectively enrolling patients.

This study aims to construct a retrospective-prospective long-term follow-up cohort and management system for aortic dissection through a multicentre collaborative network. The duration of the study will be divided into retrospective and prospective components. The retrospective study will collect cases of aortic dissection of different aetiologies from 2003-2022; the prospective study is expected to collect cases of aortic dissection from 2022-2030. The study is expected to assess the disease characteristics, progression patterns, clinical features, natural course and long-term prognosis of aortic coarctation.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-80 years;
* Meet diagnostic criteria for aortic dissection.

Exclusion Criteria:

* Age \<18 years or \>80 years;
* Women who are pregnant and breastfeeding;
* Patients and their families refuse or are unable to sign the informed consent form.
School Based Physical Activity Interventions and Its Impact on Wellbeing and Educational Outcomes

A school based Physical Activity intervention for pupils (8-9 years old) to promote fitness and wellbeing

The experimental group will participate in a 24 week multi-component programme that includes four strands:

* A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).
* 'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week
* After schools club (not compulsory) featuring mind-set component delivered by external facilitators
* Healthy kidz app with reward system

The control group will continue doing physical activity including physical education as is normal for their school

All groups will participate in fitness assessments at week 1 and week 24 of the programme and pupils will also complete questionnaires based on measures described above at week 1 and week 24.

Eligibility Criteria:
Inclusion Criteria:

* aged 8-9 years
* enrolled in participating school

Exclusion Criteria:

* Unable to give informed consent
* Presence of an underlying medical conditions
* Already enrolled in a physical activity intervention
Combination of Duloxetine and Pregabalin to Improve Postoperative Pain

Postoperative pain is mediated by different mechanisms at multiple neural sites. Thus, multimodal analgesics can reduce the postoperative pain. Although Opioids are considered the analgesics of choice to treat moderate to severe pain, their use carries the risk of side effects and hyperalgesia. Multimodal analgesia can be achieved by combining different analgesics and different methods of administration, to provide better analgesia synergistically compared with conventional analgesia. Therefore,lower doses for each drug can be provided with fewer overall side-effects obtained from individual compounds.

Recently, antidepressants such as duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), have accomplished pain relief in persistent and chronic pain as in fibromyalgia, postherpetic neuralgia, diabetic neuropathy, osteoarthritis and musculoskeletal pain. The analgesic effect of duloxetine is attributed to its ability to enhance both serotonin and norepinephrine neurotransmission in descending inhibitory pain pathways. Moreover, some studies have promoted its use to improve the quality of recovery after surgery and reduce the acute postoperative pain after knee replacement surgery , mastectomy , hysterectomy , and after spine surgery. In addition it can improve postoperative quality of recovery through mood improvement that can be helpful in the postoperative period.

The main objective of the present study was to examine perioperativelythe analgesic efficacy with the combination of duloxetine and prgabalinon postoperative pain when given as part of a multimodal pain strategy in patients undergoing surgery on liosuction. In addition to evaluating the patient's satisfaction and the adverse effects related to the combination of both medications.


Eligibility Criteria:
Inclusion criteria:

* Patients aged from 18 to40 years.
* ASA I-II.
* undergoing elective mega -liposuction surgery
* BMI from 18 to 50 kg/m2

  2. Exclusion criteria:
* Patient refusal
* Contraindication or chronic use (consistent use for longer than 3 months) to any of the study drugs ASA III-IV.
* Patients aged less than 18 or more than 40.
* Body mass index \>50.
* Suffered from severe psychiatric disease or drug addiction;
* Chronic opioid consumption,
* a history of regular sedatives or anticonvulsants intake, serious organ disease or dysfunction
* inability to use a PCA device
* History of parenteral or oral analgesic intake within the last 48hours.
Neuroelectrical Biomarkers for Alzheimer's Disease Stages

Recent diagnostic criteria for Alzheimer's disease (AD) recognize an extended spectrum of AD stages as part of the disease, including a preclinical stage. This underscores the importance of early prognosis of AD when it is still possible to influence the course of the disorder. The investigators propose a comprehensive project which will target the data-driven modeling of the disease development. This goal will be achieved by creating and validating a battery of new sensitive biomarkers for clinical evaluation and prediction of AD in individuals. The AD-related brain changes will be assessed by noninvasive functional EEG measured during an episodic memory task in subjects at different stages of AD, as well as in healthy controls. The novel functional biomarkers will be extracted using a rigorous multistage selection procedure involving advanced methods for feature extraction, as well as statistics and classification for optimal selection. The ESTIMATE project will serve as a first step in an extensive array of research procedures which will enable the early clinical identification of Alzheimer's disease in elderly individuals who could then take advantage of preventive pharmaceutical therapies.


Eligibility Criteria:
Inclusion Criteria:

* Age: 70-85 years old
* Presence of memory impairment
* Completed educational level: middle school
* Visual and auditory acuity: normal or corrected-to-normal

Exclusion Criteria:

* Monogenic AD
* Presence of a neurological disorder
* Stroke that has occurred in the last three months
* Prohibited medications
* Residence in skilled nursing facility
* Illiteracy, is unable to count or to read
* Claustrophobia
Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.

The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to a control/sham device.

Avulux™ is intended to decrease the impact of headache and migraine on normal daily life and the ability to function, and reduce the frequency and severity of headache, in adult patients diagnosed with episodic migraine headache or chronic migraine.

Avulux™ consists of a pair of optical filters in the form of spectacle lenses, provided in standard spectacle frames or as clip-on units, coated with a thin film that effectively blocks light at specified wavelength ranges while minimizing distortion of the visible spectrum. The optical filters block a portion of the optical spectrum that is suspected to stimulate photophobic responses that trigger some, and exacerbate most, migraines.

Eligibility Criteria:
Inclusion Criteria:

1. Patient is 18 years or older
2. Patient is willing and able to provide written informed consent
3. Patient is willing and able to complete all scheduled study visits
4. Diagnosis of migraine, based on the following primary headache characteristics:

   1. At least 5 attacks fulfilling criteria b-d:
   2. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
   3. Headache has at least two of the following characteristics:

      * unilateral location
      * pulsating quality
      * moderate or severe pain intensity
      * aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
   4. During headache at least one of the following:

      * nausea and/or vomiting
      * photophobia and phonophobia
   5. Not attributed to another disorder

Exclusion Criteria:

1. Patients with other light sensitive conditions, such as iritis.
2. Patients who have less than 4 headache days per month
3. Patients who have chronic daily headaches.
4. Patients who have had any change in their migraine treatment within the 4 weeks prior to the trial onset.
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling

The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH
* Age ≥ 18 years of age and ≤80 years old.
* Newly diagnosed with HNSCC cancer.
* No prior therapy for HNSCC cancer is permitted for enrollment in the trial.
* All subjects must be able to comprehend and sign a written informed consent document.

Exclusion Criteria:

* Pregnant or may become pregnant during metformin administration.
* On metformin for any reason during the preceding 4 weeks.
* Diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas.
* Received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin. These patients cannot start investigational metformin until 48 hours have elapsed from contrast administration. Subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded.
* Plasma alanine aminotransferase greater than 40 IU/dL.
* Plasma aspartate aminotransferase greater than 45 IU/dL.
* Plasma creatinine level greater than 1.3 mg/dL.
* Plasma alkaline phosphatase greater than 190 IU/dL.
* Plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
* History of congestive heart failure.
* Myocardial ischemia or peripheral muscle ischemia.
* Sepsis or severe infection.
* History of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
* Scheduled for definitive HNSCC cancer surgical resection less than two weeks from enrollment or greater than five weeks from enrollment.
* History of hepatic dysfunction or hepatic disease.
* Excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men.

All medications are permitted except those that are contraindicated with metformin under current FDA recommendations.
An Update on Intracerebral Hemorrhage

The intracerebral hemorrhage study is a multicenter , combination of prospective and retrospective observational cohort study led by Dr. Muhammad Junaid Akram, PhD scholar at Chongqing Medical University. Prof Dr. Qi Li will be the senior consultant for the study. The study will be focusing on natural history, epidemiological , radiological, rehabilitative and clinical aspects as well as the effect of various treatments on the hemorrhagic patients.

The study related data of the patients diagnosed with intracerebral hemorrhage will be collected in prospective and retrospective ways. The prognostic data for the patients will be assembled and collected via using different outcome measures at different points of time.

The study will be used to address the several key issues related to intracerebral hemorrhage. The demographics, scores based upon disease severity , mRS, GCS, NIHSS scores will be recorded at baseline and in the prospective and retrospective ways. The data obtained from the registered patients will be used for future use , critical review by expert neurologists, neurorehabilitative experts for further use and review.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years Patients willing to participate via signing a consent form' Patients diagnosed with CT-Confirmed spontaneous intracerebral hemorrhage (ICH) Patients willing to participate in the follow up assessment

Exclusion Criteria:

* Not willing to participate Secondary ICH to hemorrhagic infarction or tumor bleeding etc. Traumatic ICH
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States Oncology Network (USON) iKnowMed (iKM) electronic health records (EHR) database.


Eligibility Criteria:
Inclusion Criteria:

* Participants diagnosed with Stage IIIA melanoma during identification period
* Participants underwent sentinel lymph node biopsy (SLNB) (index-event) during identification period
* Participants with a complete surgical resection at or following SLNB during the identification period
* Participants received nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant therapy in USON post-index event during the identification period (i.e., within 12 weeks of SLNB/resection); or received no treatment during the index period
* Participants receiving care at a USON site utilizing the full EHR capacities of the iKM database at the time of treatment
* Participants with ≥2 visits within the USON during the observation period
* Participants ≥18 years of age at first clinical diagnosis of melanoma

Exclusion Criteria:

* Participants with a previous systemic therapy prior to index
* Participants with a diagnosis of ocular or uveal melanoma during the study period
* Participants with a previous nonmelanoma cancer without complete remission for more than 3 years prior to index
* Participants with mucosal or acral melanoma during the study period
* Participants with systemic use of glucocorticoids during at the initiation of adjuvant therapy
* Participants enrolled in a clinical trial at any time during the study period
* Participants with a diagnosis and receiving treatment for another malignancy during the study observation period
Disturbing Factors in the Operating Room

Observation of disturbing factors in the operating room and comparison between day and night shift. The investigators have chosen to observe kidney transplantations, since this type of operation has the same priority during day and night. Stress levels of surgeons will be measured using the HealthPatch.


Eligibility Criteria:
Inclusion Criteria:

* All vascular surgeons who are able to perform elective as well as postmoral kidney transplantations

Exclusion Criteria:

-